The deadline to comment on FDA's generative AI paper is Oct 19, 2026. We explain why professionals in pharma manufacturing should weigh in.
|Articles|June 2, 2001
- Pharmaceutical Technology-06-02-2001
- Volume 25
- Issue 6
Measurement of Intrinsic Drug Dissolution Rates Using Two Types of Apparatus
The evaluation of the intrinsic dissolution rate of an active pharmaceutical ingredient can be used to demonstrate chemical purity and equivalency. The authors used a rotating disk system and a stationary disk system to determine the intrinsic dissolution rates of various model drugs.
Advertisement
Articles in this issue
over 25 years ago
Viral Clearance Strategies for Biopharmaceutical Safetyover 25 years ago
Outsourcing Outlookover 25 years ago
Managing Risks and Resourcesover 25 years ago
Blister News: COC Resin, Foil, and Lidding Innovationsover 25 years ago
Managing the Risks in Outsourcingover 25 years ago
Systemic Drug Delivery via the Buccal Mucosal RouteAdvertisement
Related to this article
The FDA expanded Anktiva to BCG-unresponsive papillary-only NMIBC using existing CIS trial data, a precedent with implications for development timelines and supply planning.
AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
Ishani Maharaj of Ingredients + Specialties from Univar Solutions explains how to stabilize GLP-1 multi-agonists, weigh delivery formats, and qualify novel excipients and suppliers.
MASH and cardiomyopathy AI collaboration: AstraZeneca pays insitro $40M upfront for target discovery, then leads clinical development and CMC planning.
Boyang Wang, Immortal Dragons, discusses how the FDA’s Expedited IND Pilot must prove efficiency as sponsors chase the fastest route to valid first-in-human data.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
The FDA’s Rare Disease Framework Initiative brings risk-based CMC review and pre-approval inspections into scope for sponsors, CDMOs, and quality teams.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Formulation Strategies for Next-Generation Multiagonists
2
First-in-Human Trial Speed: Why FDA Trails China
3
PharmTech AI Pulse Check: Why Pharma Should Weigh In on FDA's Generative AI Paper
4
MASH and Cardiomyopathy Targets: Why AstraZeneca Chose insitro’s AI
5